The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAThe effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review This report should be referenced as follows:Dinnes J, Cave C, Huang S, Major K, Milne R.The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review. 2001;5(13). Health Technol Assess Health Technology Assessment is indexed in Index Medicus/MEDLINE and Excerpta Medica/EMBASE.Copies of the Executive Summaries are available from the NCCHTA website (see opposite). NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Rapid reviews are completed in a limited time to inform the appraisal and guideline development processes managed by NICE. The review brings together evidence on key aspects of the use of the tec...

A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma

“…Eight full reports of six studies were identified for inclusion in the main review (Dinnes et al, 2001). Only the five studies providing effectiveness data for temozolomide in patients with AA or GBM are reported here (Table 1).…”

“…More detailed discussion of factors that affect various outcome measures and how the included studies addressed these factors can be found in the full report (Dinnes et al, 2001). …”

“…Study quality was assessed using a shortened version (Dinnes et al, 2001) of a checklist developed originally for an epidemiological review (Spitzer et al, 1990). The scale developed by Jadad et al (1996) was used to assess RCTs.…”

“…This paper presents the systematic review of the effectiveness literature only. The full report (available in the HTA monograph series) also presents the economic evaluation that was conducted (Dinnes et al, 2001). …”

NICE verdict on Temozolomide: where next?

“…The systematic Cochrane type review of published articles (described in detail in the full publication (Dinnes et al, 2001) concludes that the evidence base for the use of Temozolomide in malignant glioma is 'weak and few strong conclusions can be drawn regarding its effectiveness' (Dinnes et al, this issue). This is in stark contrast to the description of the agent during its launch as 'the most important advance in brain cancer treatment for the past 20 years'.…”